Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study

References

• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun;26(18):3063–3072. %20.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug;39(6):713–734.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Klöppel G. et al. WHO classification of tumours of endocrine organs. WHO Classification of Tumours. 4th. Vol. 10, ISBN-13 (Print Book)978-92-832-4493-62017. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp? codlan=1&codcol=70&codcch=4010
   Google Scholar
• ENETS, O’Toole D, Kianmanesh R, Caplin M, et al. ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103(2):117–118.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller -H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1; 27(28):4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17; 371(3):224–233.
   PubMed Web of Science ®Google Scholar
• Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104(1):26–32.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016 Mar;23(3):191–199.
   PubMed Web of Science ®Google Scholar
• Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013 Nov 14; 19(42):7258–7266.
   PubMed Web of Science ®Google Scholar
• Sikkens EC, Cahen DL, Kuipers EJ, et al. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Pract Res Clin Gastroenterol. 2010 Jun;24(3):337–347.
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W, Lembcke B, Folsch UR, et al. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. Am J Med. 1987 May 29;82(5B):49–54.
   PubMed Web of Science ®Google Scholar
• Lembcke B, Creutzfeldt W, Schleser S, et al. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion. 1987;36(2):108–124.
   PubMed Web of Science ®Google Scholar
• Dumasy V, Delhaye M, Cotton F, et al. Fat malabsorption screening in chronic pancreatitis. Am J Gastroenterol. 2004 Jul;99(7):1350–1354.
   PubMed Web of Science ®Google Scholar
• McCallum L, Lamarca A, Valle JW. Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. Cancer Research Frontiers. 2016 Sept;2(3):352–367. .
   Google Scholar
• Watson L. Exocrine insufficiency and pancreatic enzyme replacement therapy in pancreatic cancer. Clin Oncol (R Coll Radiol). 2010 Jun;22(5):391.
   PubMed Web of Science ®Google Scholar
• Merola E, Panzuto F, Delle FG. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget. 2017 Jul 11;8(28):46624–46634.
   PubMedGoogle Scholar
• ACE-27. ACE-27; Adult Comorbidity Evaluation-27 index: http://www.rtog.org/LinkClick.aspx?fileticket=oClaTCMufRA%3D&tabid=290. Accessed 2015 Jan. 2015.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• CTCAE. Common terminology criteria for adverse events: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf accessed 2015 Jan. 2015.
   Google Scholar
• McLachlan SA, Devins GM, Goodwin PJ. Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer. 1998 Mar;34(4):510–517.
   PubMed Web of Science ®Google Scholar
• Yadegarfar G, Friend L, Jones L, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013 Feb 5;108(2):301–310.
   PubMed Web of Science ®Google Scholar
• Scott NS EORTC QLQ-C30 reference values. July2008. Last accessed 2017 Apr. Available from: http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference_values_manual2008.pdf
   Google Scholar
• Derogar M, Van Der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol. 2012 Jan;51(1):10–16.
   PubMed Web of Science ®Google Scholar
• Dominguez-Munoz JE, Hardt D, Lerch MM, et al. Potential for screening for pancreatic exocrine insufficiency using the Fecal Elastase-1 Test. Dig Dis Sci. 2017 May;62(5):1119–1130.
   PubMed Web of Science ®Google Scholar
• Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011 May 31;8(7):405–415.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003 Jul 15;21(14):2689–2696.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016 Dec;17(18):2487–2498.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014 Sep;19(9):930–936.
   PubMed Web of Science ®Google Scholar
• Langbrandtner J, Hüppe A, Jessen P, et al. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol. 2017 Sep 4;10:215–227.
   PubMed Web of Science ®Google Scholar
• Martins CP, Chaves CHA, Castro MGBD, et al. Prevalence of small intestine bacterial overgrowth in patients with gastrointestinal symptoms. Arq Gastroenterol. 2017 Apr;54(2):91–95.
   PubMedGoogle Scholar